Abstract. Melittin is a 26 amino acid residue antimicrobial peptide with known antitumor activity. In the present study, a novel peptide TT-1, derived from melittin and contained only 11 amino acids, was designed, and its antitumor effect was investigated. The present study is aimed to elucidate the effects and relative mechanisms of TT-1 on a human thyroid cancer cell line (TT) in vitro and in vivo. Cell viability assays, Annexin V/propidium iodide assays, western blotting and quantitative reverse transcription polymerase chain reaction were performed. Furthermore, a tumor-xenograft model was established to investigate the apoptotic mechanisms of TT-1 on TT cells. The results obtained indicated that TT-1 was able to suppress the proliferation of TT cells and exhibited low cytotoxicity to normal thyroid cells in vitro. The apoptotic rates of TT cells were also increased following TT-1 treatment. Additionally, TT-1 stimulated caspase-3, caspase-9 and Bax, and inhibited B-cell lymphoma 2 mRNA and protein expression. Finally, it was also demonstrated that TT-1 is able to markedly suppress tumor growth in a TT-bearing nude mouse model. In summary, TT-1 may inhibit the proliferation of TT cells by inducing apoptosis in vitro and in vivo, indicating that TT-1 may be a potential candidate for the treatment of thyroid cancer.
Introduction
Human cancer remains a leading cause of mortality worldwide despite recent advances in therapeutic methods (1) . Incidences of thyroid cancer have steadily increased, and the disease has become the most prevalent endocrine malignancy worldwide (2) . Thyroid cancer has an age-standardized incidence distribution and is estimated to occur in 9.1 per 100,000 females and 2.9 per 100,000 males in developed countries (3) According to the most recent World Health Organization classification of thyroid tumors, the disease classification includes papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer, and anaplastic thyroid cancer (4) . PTC and FTC are differentiated thyroid cancers and account for >90% of all thyroid malignancies (5) . The classic treatment of thyroid cancer is a total thyroidectomy followed by radioiodine treatment (5) . Chemotherapy and biochemotherapy have also been used in the treatment of advanced melanoma. However, these treatments lack sufficient efficacy, and their toxicity and significant side effects greatly restrict their clinical application (6) . Therefore, it is necessary to find an efficient and low-toxic anticancer drug for patients with thyroid cancer.
Antimicrobial peptides (AMPs) are natural peptides found in a wide range of organisms, including prokaryotes, insects, fish, amphibians and mammals (7) . AMPs are cationic and amphiphilic molecules and have a wide range of characteristics based on peptide sequences, sizes, structural motifs and the presence of disulfide bonds (8) . The molecules possess broad antimicrobial activity by binding to target bacteria to disrupt the membrane structure or by inhibiting fundamental bacterial metabolism (9) . In addition to the antimicrobial activity, previous studies have also demonstrated that AMPs can selectively kill cancer cells because the membrane proteins of cancer cells are negatively charged due to glycosylation (10) .
Melittin, a major peptide component of bee venom (Apis mellifera), is a cationic peptide comprising a small linear peptide of 26 amino acid residues (11, 12) . Melittin was demonstrated to exert broad antimicrobial activity against bacteria by intercalating into cell membranes and causing changes in the membrane properties (13) . Previous studies demonstrated that melittin also has in vitro anticancer activities against several TT-1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl-2 and Bax cancerous cells, including renal, lung, breast and bladder cells (14, 15) . However, high synthesis cost, high cytotoxicity and low stability have prevented the development of melittin as a promising anticancer agent (16, 17) .
TT-1 is a mutant of melittin generated by a reduction of the peptide chain length and replacing glycine residues with lysine residues. The peptide sequence was changed from ʻGIG AVL KVL TTG LPA LIS WIK RKR QQʼ to ʻKIK AVL KVL TTʼ, which contained only 11 amino acids. The TT-1 mutant retained the amino-terminal active site region of melittin, has an increased hydrophobicity and a decreased net charge, which indicates a higher stability and lower toxicity compared with melittin (18, 19) . The present study investigated the activity and the mechanism of TT-1 in the treatment of human thyroid cancer TT cells. The results revealed that TT-1 suppressed the proliferation of TT cells by inducing apoptosis via upregulation of Bax, downregulation of B-cell lymphoma-2 (Bcl-2) and the activation of caspase-3 and -9 at transcriptional and translational levels. These interferences further inhibited TT tumor growth in nude mice. These results highlighted the therapeutic potential of TT-1 in thyroid cancer.
Materials and methods
Peptide synthesis. TT-1 (KIKAVLKVLTT) was synthesized by GL Biochem (Shanghai, China) via a stepwise solid phase methodology. The resulting peptide was purified via a Sephadex gel column and high-performance liquid chromatography to achieve a >98% homogeneity of the purified peptide. The peptide information was analyzed using the antimicrobial peptide database (http://aps.unmc.edu/AP/main.html). After entering the home page of the website, 'Calculation & Prediction' was chosen and the amino acid sequence of the peptide was entered in the newly opened web page, which then displays information on the peptide.
Cell lines and regents. The human thyroid cancer cell line TT and a normal human thyroid follicular epithelial cell line Nthy-ori3-1, obtained from the American Type Culture Collection (Manassas, VA, USA), were maintained as previously described (20) . Briefly, TT and Nthy-ori3-1 were cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum provided by Gibco (Thermo Fisher Scientific, Inc.), 100 U/ml penicillin, and 100 U/ml streptomycin. The cells were cultured at 37˚C with 5% CO 2 . MTT, sodium pyruvate and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Annexin V-fluorescein (AV) and propidium iodide (PI) were purchased from Invitrogen (Thermo Fisher Scientific, Inc.). Fluorometric assay kits for measuring the activities of caspase-3 and 9 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Monoclonal antibodies against Bax (cat. no. sc-52895; dilution: 1:1,000) and Bcl-2 (cat. no. sc-509; dilution: 1:1,000) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The easy Plus Mini kit, iScript Select cDNA Synthesis kit, SyberGreen qPCR primer and iCycleriQ™ multicolor real time PCR detection system were purchased from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China).
Cell viability assay. To evaluate the effects of TT-1 on TT cells and Nthy-ori3-1 cells, the MTT assay was conducted as previously described (21) . Briefly, the cells were cultured in 96-well plates at a density of 5x10 3 cells/well and allowed to attach for 12 h. Different concentrations (0-32 µg/ml) of TT-1 were added to the cells, and the cells were further incubated for 24, 48 and 72 h at 37˚C. Following incubation, the cells were incubated with MTT solution (5 µg/ml) for 4 h at 37˚C followed by the addition of 150 µl DMSO per well and then shaken for 5 min prior to measuring the absorbance at 490 nm.
Cell apoptosis assay. Cell apoptosis assays (22) were conducted by double staining with AV and propidium iodide (PI) kit (ebioscience; Thermo Fisher Scientific, Inc.) to investigate whether TT-1 is able to induce apoptosis in TT cells. TT cells (5x10 5 cells/well) were placed in 6-well plastic plates 24 h prior to the TT-1 treatments. Following the replacement of medium supernatant, various concentrations of TT-1 (0-8 µg/ml) diluted in PBS were added. Following incubation at 37˚C with 5% CO 2 for 48 h, the cells were harvested. The AV/PI assays were performed following the manufacturer's instructions. Subsequently, the cell samples were analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA) and the data was analyzed by the flowjo 9 software (FlowJo LLC, Ashalnd, OR, USA).
Western blot analysis for Bax and Bcl-2 protein expression.
The effects of TT-1 on Bax and Bcl-2 expression of TT cells were examined by western blotting as previously described (23) . TT cells treated with or without TT-1 (0-8 µg/ml) for 48 h were homogenized in lysis buffer and centrifuged at 10,000 x g for 20 min at 4˚C. Then, the supernatants were analyzed for protein content by BCA assay. Equal amounts of protein sample (50 µg) were loaded and separated by 12% SDS-PAGE and electrically transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Afterward, the membranes were blocked in TBST supplemented with 5% bovine serum albumin for 2 h at 37˚C followed by incubation at 4˚C overnight in primary anti-Bax and anti-Bcl-2 antibodies, and finally incubation at 37˚C for 1 h with secondary antibodies [goat anti-mouse IgG (H&L) (HRP), cat. no. KC-MM-035; goat anti-rabbit IgG (H&L) (HRP) or cat. no. KC-RB-035; both diluted to 1:5,000; both Zhejiang Kangchen Biotech Co., Ltd., Wuhan, China]. Following washing with TBST three times for 10 min, the membranes were exposed by a chemiluminescence (ECL) detection kit. Bio-Imaging Image Lab 6.0 System software (Image Lab, Hercules, CA, USA) was used to detect the blot. Meanwhile, all blots were stripped and reprobed using a monoclonal anti-β-actin antibody (Santa Cruz Biotechnology, Inc.; grant no. sc-47778; dilution 1:1,000) to determine whether the proteins were equally loaded.
Determining the activity of caspase-3 and -9. The effects of TT-1 on the activity of caspase-3 and -9 in TT cells were determined using a fluorometric assay kit (Calbiochem; EMD Millipore) according to the manufacturer's protocol as previously described (24) . Briefly, TT cells were treated with TT-1 (0-8 µg/ml) for 48 h and harvested prior to the preparation of cell lysates. Then, the reaction buffer and the corresponding fluorogenic peptide substrate, Ac-DEVD-AMC (caspase-3) and Ac-LEHD-AMC (caspase-9), were added to the cell lysates and incubated for 2 h at 37˚C in the dark. The activity of caspase-3 and -9 in TT-1-treated TT cells were investigated using a microplate reader at 390 nm (excitation) and 500 nm (emission).
Quantitative reverse transcription polymerase chain reaction (RT-qPCR).
The effects of TT-1 on the Bax, Bcl-2, caspase-3 and caspase-9 RNA expression in TT cells were examined by RT-qPCR as previously described (25, 26) . Total RNA was extracted from TT cells with or without TT-1 treatment (0-8 µg/ml for 48 h) by using Trizol reagent and then purified with an RNeasy Mini kit (Qiagen GmbH, Hilden, Germany). Afterward, qPCR was conducted with an ABI PRISM 7300 sequence detection system (Applied Biosystems; Thermo Fisher Scientific Inc.), and 3 wells were used for each reaction. The relative mRNA expression was calculated using the comparative Cq (2 −ΔΔCq ) method (27) . The primers were as follows: Caspase-3 forward, 5'-AGGAAGGTGGCAACG-3' and reverse, 5'-CGC CAA ATC TTG CTA AT-3'; caspase-9 forward, 5'-GGC TGT CTA CGG CAC AGA TGG A-3' and reverse, 5'-CTG GCT CGG GGT TAC TGC CAG-3'; Bax forward, 5'-GGC CCA CCA GCT CTG AGC AGA-3' and reverse, 5'-GCC ACG TGG GCG GTC CCA AAG T-3'; Bcl-2 forward, 5'-GTG GAG GAG CTC TTC AGG GA-3' and reverse, 5'-AGG CAC CCA GGG TGA GCA A-3'.
TT-xenograft mouse model and TT-1 administration in vivo.
Ethical approval for the present study was obtained from the Institutional Animal Care and Use Committee at Jilin University (Jilin, China). A total of 40 4-week-old nude mice (male; weight, 16-18 g) were purchased from the Jilin University Bethune School of Medicine and housed in a rodent facility at 22˚C with a 12 h light-dark cycle. The mice were provided with continuous standard rodent chow and water. TT cells (1x10 7 ) were collected in the logarithmic phase of growth, diluted with normal saline and then inoculated intradermally into the hind flank. The tumors were inoculated for 12 days. The nude mice were randomly (n=10 per group) divided into four groups, a model control group administered with normal saline and three TT-1-treated groups, which were administered at 0.04, 0.2 or 1 mg/kg body weight with intra-tumor injection three times a week. At the indicated time points, the mice from all the groups were sacrificed by overdose of anesthetics 24 h following final administration. Tumor weights of the mice were measured. Additionally, the tumor volume of each mouse was measured every three days during the treatment. The antitumor activities were expressed as inhibitory rate (%) and calculated as [(A-B)/A] x100%, where A and B were the mean tumor weight of the model and TT-1 groups, respectively. The tumor volumes (TV) were calculated using the following formula: TV=1/2xaxb 2 , where a and b are the long and short diameters of the tumors in each mouse, respectively. Statistical analysis. All experiments conducted in the present study were performed in triplicate. The data are presented as the mean ± standard deviation. Statistical analysis was performed by Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

TT-1 selectively inhibits the viability of TT cancer cells but not normal human thyroid cells.
To determine the cytotoxic activity of TT-1, MTT assay was conducted. As shown in Fig. 1A , the viabilities of normal human thyroid follicular epithelial cells Nthy-ori3-1 did not decrease in response to TT-1 treatment at concentrations up to 8 µg/ml for 48 h. Furthermore, treatment with TT-1 significantly inhibited the proliferation of TT cells in a dose and time-dependent manner (Fig. 1B and C) . The 50% inhibitory concentrations (IC 50 ) of TT-1 on TT cells were 18.23±2.81, 3.87±0.34, 2.76±0.32 µg/ml at 24, 48 and 72 h, respectively. Specifically, at 4 µg/ml TT-1, the viability of TT cells at 48 h decreased to 47.8%, which was much lower compared with the viability of Nthy-ori3-1 cells. The results showed that TT-1 exhibited high cytotoxicity on TT cancer cells and low cytotoxicity to normal human thyroid cells.
TT-1-induces apoptosis of TT cells in vitro.
To investigate whether apoptosis was involved in TT-1-induced anti-TT activity, an AV/PI assay was conducted. The cells double-labeled with AV and PI, which discriminated between unaffected and apoptotic cells. AV-positive cells indicated the loss of membrane polarity, which leads to the complete loss of membrane integrity and subsequently, to apoptosis and PI infiltration. As shown in Fig. 2 , treatment with TT-1 induced apoptosis of TT cells in a dose-dependent manner. Specifically, the average apoptotic cell accumulations reached 12.31, 18.62 and 31.07% for 2, 4 and 8 µg/ml TT-1 concentrations, respectively (Fig. 2B) . Apoptosis may be one of the mechanisms by which TT-1 is able to prevent proliferation.
TT-1 upregulates Bax and downregulates Bcl-2 expression in
TT cells. The Bcl-2 family of proteins is known to have critical roles in regulating apoptosis (28) . Therefore, the authors of the present study examined the expression of Bax, the pro-apoptotic protein, and Bcl-2, the anti-apoptotic protein, on the treatment of TT cells with TT-1 at the level of transcription and translation. As shown in Fig. 3A , the levels of Bax mRNA in TT cells was upregulated by TT-1 treatment in a dose-dependent manner.
Additionally, treatment with TT-1 decreased the levels of Bcl-2 mRNA in TT cells in a dose-dependent manner (Fig. 3B) . Specifically, at 8 µg/ml TT-1, the mRNA expression of Bax and Bcl-2 were 2.23-fold higher and 0.56-fold lower, respectively compared with the control group. These changes were confirmed at the protein level using a western blot analysis (Fig. 3C-E) .
TT-1 treatment activates the caspase-3 and -9 in TT cells.
As apoptosis was observed in TT-1-treated TT cells, the present study measured the activity of different caspases as key factors of apoptosis using a fluorometric assay (Fig. 4) . The results showed that caspase-3 and -9 were activated in the TT-1-treated TT cells in dose-dependent manners from 2-8 µg/ml (Fig. 4A  and C) . Furthermore, similar results were obtained in the RT-qPCR assays. The levels of caspase-3 and -9 RNA in the TT cells increased following exposure to TT-1 ( Fig. 4B and D) .
TT-1 treatment suppresses the tumor growth in TT-bearing mice.
To investigate whether TT-1 is able to inhibit tumor growth in vivo, a TT xenograft model was established. Following TT-1 treatment, the volume and weight of the tumors were measured. As indicated in Fig. 5A -C, TT-1 was able to suppress the tumor growth in nude mice in a dose dependent manner. Compared with the model group, the tumor inhibitory rates of the TT-1-treated groups were 30.00, 34.28 and 55.71% at treatment concentrations 0.04, 0.2 and 1 mg/kg, respectively. The weight of the animals in the TT-1-treated groups to those of the model control group (Fig. 5D) , indicating that there were no significant changes in body weight during TT-1 treatment. Therefore, cancer cell growth was significantly suppressed in mice treated with TT-1 without a significant loss in body weight.
Discussion
Thyroid cancer is the most frequent neoplasm of the endocrine system (2). The prognosis of thyroid cancer is excellent at the initial stages of disease. However, for advanced or metastatic diseases, limited therapeutic options are available (29) . Additionally, conventional chemotherapy and radiotherapy often have severe side effects on healthy cells and tissues (30) . As a result, the most promising drugs are those with low cytotoxicity, target selectivity and availability for chronic treatment.
Antimicrobial peptides have recently attracted significant attention as novel anticancer agents due to their novel mechanisms, decreased likelihood of drug resistance, and low intrinsic cytotoxicity (31) . Melittin, which consists of 26 amino acid residues, is a cationic, hemolytic peptide isolated from honeybee venom. Previous studies have demonstrated that melittin has antibacterial, anti-arthritic and anti-inflammatory activities in various cell lines (6) . Additionally, melittin has been shown to be a promising anticancer drug. A number of types of cancer cells, including renal, lung, breast, and bladder cells, have been reported to be selectively killed by melittin in vitro (14) . In the present study, the authors designed a novel peptide, TT-1, based on the amphipathic structure of melittin. The peptide sequence of TT-1 was KIKAVLKVLTT, consisting of only 11 amino acids, which is much shorter than the peptide sequence length of melittin. The antimicrobial peptide database indicated that total hydrophobic ratio of TT-1 was 54% and the net charge was 5. These parameters indicated that TT-1 would be effective in treating cancer cells. Therefore, the relative activity and mechanism of TT-1 were further investigated.
It has been reported that melittin exhibits cytotoxic activity toward tumors and normal cells (32) . In the present study, an in vitro study of the cytotoxic effect of TT-1 revealed that TT-1 was able to inhibit the proliferation of TT cells in a dose and time-dependent manner but had no significant growth inhibitory effects on normal thyroid follicular epithelial Nthy-ori3-1 cells. Therefore, TT-1 displayed selective anticancer activity. Apoptosis, a very tightly programmed cell death with distinct biochemical and genetic pathways (33) , is generally identified via specific morphological cellular characteristics, including cell shrinkage, nuclear or cytoplasmic fragmentation and chromatin condensation (34) . A class of cysteine proteases, including caspase-3, -8 and -9, is commonly involved in the apoptotic pathways (35) . On the other hand, the Bcl-2 family also has an important role in the regulation of apoptosis (36) . Defects in apoptotic mechanisms have important roles in tumor pathogenesis, which allows neoplastic cells to survive over intended lifespans, subverts the need for exogenous survival factors and provides protection from oxidative stress and hypoxia as the tumor mass expands (32) . Therefore, the ability to induce apoptosis is necessary for effective anticancer therapies (37) . In the present study, double staining of cells with AV/PI revealed that TT-1-induced apoptosis may be one of the mechanisms by which TT-1 prevents the growth of TT cells in vitro.
Bcl-2 and Bax, members of the Bcl-2 family of proteins, are important components of ischemia-reperfusion injury-induced apoptosis (28) . These two proteins can form either homodimers or heterodimers, which depends on the levels of each component that is present. Bax forms a heterodimer with Bcl-2 and functions as an apoptotic activator by increasing the opening of the mitochondrial voltage-dependent anion channel, which leads to the loss in membrane potential (38) . Therefore, high expression of Bcl-2 is able to inhibit apoptosis, while high expressions of Bax can stimulate apoptosis. A change in the expression ratio of these two factors determines whether apoptosis occurs (39) . In the present study, the results shown in Fig. 3 suggest that the apoptotic mechanism of TT-1 in TT cells include the downregulation of Bcl-2 expression and the upregulation of Bax expression at the level of transcription and translation.
Additionally, caspase family members have major roles in cell apoptosis (40) . The caspase cleavage cascade begins with initiator caspase being activated by intrinsic or extrinsic pathways. In the present study, the authors examined two typical caspase family members, caspase-3 and -9. Caspase-3 is an effector caspase that mediates the cleavage of many proteins, while caspase-9 is the key initiator caspase in the intrinsic pathway that induces cell death and the activation of which occurs at the mitochondrial membrane (41) . The present study showed that caspase-3 and -9 mRNA levels were significantly increased in the TT-1-treated group compared with the untreated controls and indicated that TT-1 may induce the apoptosis of TT cells, which may be partly due to the activation of caspase-3 and -9 (Fig. 4) .
From these results, TT-1 exhibited a marked inhibitory effect on cell viability on TT cells in vitro, and it was also demonstrated that TT-1 exhibited anti-tumor activity on TT cells in vivo (Fig. 5) . Compared with the control, TT-1 was able to suppress the proliferation of TT cells tumor-bearing mice in a dose dependent manner, with an observed 55.71% inhibition at 1 mg/kg TT-1. This finding was further confirmed by results of TT tumor growth in vivo, and TT-1 treatment had no effect on the weight of mice, indicating that TT-1 may be a potential high efficiency and low toxicity anticancer agent.
In summary, TT-1 inhibited the proliferation of human TT cells in vitro and in vivo through the upregulation of Bax, the downregulation of Bcl-2 and the activation of caspase-3 and -9. These results further suggested that TT-1 may be a potential candidate for the treatment of thyroid cancer.
